Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma

Table S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma

<p>Over-/highly expressed genes in the primary glioblastoma when compared with glioblastoma cohort in TCGA Database.</p>

Sábháilte in:

Sonraí bibleagrafaíochta
Príomhchruthaitheoir:	Jian Wang (15048011) (author)
Rannpháirtithe:	Tobias Weiss (15048014) (author), Marian C. Neidert (15048017) (author), Nora C. Toussaint (15048020) (author), Reza Naghavian (15048023) (author), Carla Sellés Moreno (15048026) (author), Magdalena Foege (15048029) (author), Paula Tomas Ojer (15048032) (author), Gioele Medici (15048035) (author), Ivan Jelcic (15048038) (author), Daniel Schulz (15048041) (author), Elisabeth Rushing (15048044) (author), Susanne Dettwiler (15048047) (author), Barbara Schrörs (15048050) (author), Joo Heon Shin (15048053) (author), Ron McKay (15048056) (author), Catherine J. Wu (14944480) (author), Andreas Lutterotti (15048059) (author), Mireia Sospedra (15048062) (author), Holger Moch (15048065) (author), Erich F. Greiner (15048068) (author), Bernd Bodenmiller (15048071) (author), Luca Regli (15048074) (author), Michael Weller (15037908) (author), Patrick Roth (15048077) (author), Roland Martin (15048080) (author)
Foilsithe / Cruthaithe:	2025
Ábhair:	Cancer Immuno-oncology Immunotherapy Cancer vaccines Combination immunotherapy
Clibeanna:	Cuir clib leis Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!

Míreanna comhchosúla

Figure S1 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S2 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S3 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S5 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S6 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S7 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Figure S8 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Table S4 from Vaccination with Designed Neopeptides Induces Intratumoral, Cross-reactive CD4<sup>+</sup> T-cell Responses in Glioblastoma
de réir: Jian Wang (15048011)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S1 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
de réir: Hansol Lee (15054787)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S2 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
de réir: Hansol Lee (15054787)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S3 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
de réir: Hansol Lee (15054787)
Foilsithe / Cruthaithe: (2025)

Supplementary Table S4 from Intratumoral CD16<sup>+</sup> Macrophages Are Associated with Clinical Outcomes of Patients with Metastatic Melanoma Treated with Combination Anti-PD-1 and Anti-CTLA-4 Therapy
de réir: Hansol Lee (15054787)
Foilsithe / Cruthaithe: (2025)

Table S1 from Intracellular Acetyl CoA Potentiates the Therapeutic Efficacy of Antitumor CD8<sup>+</sup> T Cells
de réir: Snehanshu Chowdhury (14957031)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 1 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
de réir: Arianna Draghi (15126339)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 2 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
de réir: Arianna Draghi (15126339)
Foilsithe / Cruthaithe: (2025)

Supplementary Data 3 from Uncoupling CD4<sup>+</sup> TIL-Mediated Tumor Killing from JAK-Signaling in Melanoma
de réir: Arianna Draghi (15126339)
Foilsithe / Cruthaithe: (2025)

Table S2, S4, S5, S6 and S7 from Single-Cell Analysis Reveals a CD4<sup>+</sup> T-cell Cluster That Correlates with PD-1 Blockade Efficacy
de réir: Hiroshi Kagamu (14961732)
Foilsithe / Cruthaithe: (2025)

File_S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S1 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S2 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S3 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S4 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S5 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S6 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S7 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

Table S8 from CD25<sup>high</sup> Effector Regulatory T Cells Hamper Responses to PD-1 Blockade in Triple-Negative Breast Cancer
de réir: Stéphane Fattori (15048281)
Foilsithe / Cruthaithe: (2025)

CD38CD39 Population DEGs DS1 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
de réir: Ankita Mitra (17141783)
Foilsithe / Cruthaithe: (2025)

Table S1 from HDACi-dependent Microenvironmental Normalization Overcomes Tumor Burden–induced T-cell Exhaustion
de réir: Andrew Nguyen (17142197)
Foilsithe / Cruthaithe: (2025)

Teee Gene Signature DS2 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
de réir: Ankita Mitra (17141783)
Foilsithe / Cruthaithe: (2025)

Teee vs Treg Clusters DEGs DS3 from A Population of Tumor-Infiltrating CD4<sup>+</sup> T Cells Co-Expressing CD38 and CD39 Is Associated with Checkpoint Inhibitor Resistance
de réir: Ankita Mitra (17141783)
Foilsithe / Cruthaithe: (2025)

Supplementary Data S1 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
de réir: Maria Lozano-Rabella (15056515)
Foilsithe / Cruthaithe: (2025)

Supplementary Data S2 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
de réir: Maria Lozano-Rabella (15056515)
Foilsithe / Cruthaithe: (2025)

Supplementary Data S3 from Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics
de réir: Maria Lozano-Rabella (15056515)
Foilsithe / Cruthaithe: (2025)

Supplementary Data from PP2Ac Deficiency Enhances Tumor Immunogenicity by Activating STING–Type I Interferon Signaling in Glioblastoma
de réir: Isha Mondal (16721699)
Foilsithe / Cruthaithe: (2025)

Cross sections for dissociative recombination of ArH<sup>+</sup> and NeH<sup>+</sup> calculated using MQDT
de réir: Åsa Larson (22660418)
Foilsithe / Cruthaithe: (2025)

Image 3_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
de réir: Stefano Ugel (7402733)
Foilsithe / Cruthaithe: (2025)

Image 2_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
de réir: Stefano Ugel (7402733)
Foilsithe / Cruthaithe: (2025)

Image 4_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
de réir: Stefano Ugel (7402733)
Foilsithe / Cruthaithe: (2025)

Image 1_A comprehensive longitudinal analysis of the cellular immune response specific to the spike protein in healthcare workers vaccinated against SARS-CoV-2– ORCHESTRA Project.pdf
de réir: Stefano Ugel (7402733)
Foilsithe / Cruthaithe: (2025)

Cannot write session to /tmp/vufind_sessions/sess_5505gepak0aovp89q56pl4bbtc